On­cono­va re­ports PhI­II flop, putting high-risk MDS pro­gram on the chop­ping block

Be­lea­guered biotech On­cono­va ran in­to an­oth­er set­back Mon­day morn­ing as a Phase III for its lead pro­gram flopped once again.

The tri­al re­sults for rigosert­ib, which blocks cel­lu­lar sig­nal­ing by tar­get­ing RAS ef­fec­tor path­ways, in high-risk myelodys­plas­tic syn­drome pa­tients did not meet its pri­ma­ry end­point of im­proved sur­vival. In in­di­vid­u­als who had tried and failed treat­ment with a hy­pomethy­lat­ing agent, rigosert­ib plus best sup­port­ive care achieved over­all sur­vival of 6.4 months, com­pared to 6.3 months for pa­tients on physi­cian’s choice.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER